drugset / Trial / NCT00983801

Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer

NCT00983801

Phase 2 Completed 58 enrolled R-Pharm
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to determine whether ixabepilone is effective in the treatment of unresectable or metastatic gastric cancer in Asian participants.

Timeline

Start
2009-11
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixabepilone Small molecule 40 mg/m2 Intravenous

Indications